Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

The study is evaluating ENHERTU (trastuzumab deruxtecan) as a first-line therapy for patients with HER2-expressing (IHC 3+/2+), mismatch repair proficient (pMMR) primary advanced (stage III/IV) or ...

References: Lam C, Varghese D, Collins J, et al. Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: An observational cohort study ...

Enhertu (5.4 mg/kg) is approved in more than 30 countries for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ...

Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) improved outcomes vs chemotherapy regardless of baseline PI3K/AKT, ESR1, or BRCA1/2 status in patients with hormone receptor–positive, HER2-low or HER2 ...

AI assistance reduced the misclassification of HER2-low and HER2-ultralow breast cancers as HER2-null by 24%. An online training platform integrated with artificial intelligence (AI) can help ...

Key takeaways. Phase III Trial Explores Enhertu Combo in Endometrial Cancer: DESTINY-Endometrial01 is assessing Enhertu with rilvegostomig or Keytruda vs. chemo plus Keytruda in HER2-expressing, pMMR ...

Geriatric Use: Of the 1741 patients with HER2-positive, HER2-low, or HER2-ultralow breast cancer treated with ENHERTU 5.4 mg/kg, 24% were ≥65 years and 4.9% were ≥75 years.